Skip to main content
SpringerLink
Log in

Criteria for Selection of New Analogs of Antitumor Antibiotics

  • Chapter
Antitumor Antibiotics

  • 134 Accesses

Abstract

A highly difficult area in the application of preclinical methodology involves the selection and development of new analogs of known antitumor agents for clinical trial. There are a considerable number of analogs of alkylating agents, purine and pyrimidine antagonists, folic acid antagonists, dimethane sulfonates, benzimidazols, antibiotics of a number of subcategories, and other classes of drugs which have demonstrable activity in antitumor test models but which have remained “dormant” with respect to development, pending any experimental observations that would provide a basis for further interest. The problems involved in the selection of new analogs of antitumor antibiotics are not dissimilar from those involved in the selection of new analogs in general. It is important to examine the preclinical criteria that may be employed in an attempt to identify analogs of antitumor antibiotics that are worthy of further development for the clinic. In general, standard preclinical testing methodologies may be employed to provide data as a guide for selection. Overall, if a new analog of a known antitumor antibiotic is to justify interest, the analog must be demonstrated to possess either quantitative or qualitative superiority over the parent compound in pharmacologic, toxicologic, immunologic, tumor cytotoxic, or other biologic properties that are therapeutically favourable. In such a determination, it is important to focus specific attention on the characteristics that are limiting for the parent antitumor antibiotic in clinical use. Various preclinical criteria for selection of new antitumor antibiotics for clinical use will be discussed below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., Delena, M., Tancini, G., Bajetta, E., Musumeci, R., Veronesi, U.: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294; 405–410 (1976).

    Article  PubMed  CAS  Google Scholar 

  2. Bonmasser, E., Bonmassar, A., Vadlamudi, S., Goldin, A.: Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc. Natl. Acad. Sci. USA 66, 1089–1095 (1970).

    Article  Google Scholar 

  3. Bradner, W. T., Imanishi, H., Hirth, R. S., Wodinsky, I.: Antitumor activity and toxicity of BU-2231-A, a new bleomycin analogue. Proc. Am. Assoc. Cancer Res. 18, 35 (1977).

    Google Scholar 

  4. Casazza, A. M., Isetta, A. M., Giuliani, F., DI Marco, A.: Immunodepressive activity of daunomycin and adriamycin. In: Adriamycin Review. Staquet, M. et al (eds.) Ghent, Belgium: European Press Medikon 1975, pp. 123–131.

    Google Scholar 

  5. Detre, S. I., Davies, A. J. S., Connors, T. A.: New models for cancer chemotherapy. Cancer Chemother. Rep. Pt. II, 5 (1), 133–145 (1975).

    Google Scholar 

  6. Di Marco, A., Casazza, A. M. Pratesi, G.: Antitumor activity of 4-demethoxydaunorubicin (NSC 256,439) administered Orally. Cancer Treat. Rep. 61, (5), 893–894 (1977).

    PubMed  Google Scholar 

  7. Garibjanian, B. T., Johnson, R. K., Kline, I., Vadlamudi, S., Gang, M., Venditti, J. M., Goldin, A.: Comparison of 5-fluorouracil and ftorafur. II. Therapeutic Response and Development of Resistance in Murine Tumors. Cancer Treat. Rep. 60 (9), 1347–1361 (1976).

    PubMed  CAS  Google Scholar 

  8. Goldin, A., Johnson, R. K.: Evaluation of actinomycins in experimental systems. Cancer Chemother. Rep. Pt. I, 58, (1), 63–77 (1974).

    CAS  Google Scholar 

  9. Goldin, A., Johnson, R. K.: Experimental Grounds for Combination Chemotherapy. Excerpta Medica International Congress Series No. 353, Proc. XI Int. Cancer Cong. Florence 1974, Vol. V, pp. 308–313.

    Google Scholar 

  10. Goldin, A., Johnson, R. K.: Experimental tumor activity of adriamycin (NSC 123127). Cancer Chemother. Rep. Pt. III, 6, 137–145 (1975).

    CAS  Google Scholar 

  11. Goldin, A., Johnson, R. K.: Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy. In: Adriamycin Review. Staquet, M. et al (eds.) Ghent, Belgium: European Press Medikon 1975 pp. 37–54.

    Google Scholar 

  12. Goldin, A., Johnson, R. K.: Adriamycin activity in experimental tumors. In: Ergebnisse der Adriamycin—Therapie. Ghione, M., Fetzer, J., Maier, H. (eds.): Berlin: Springer-Verlag 1975, pp. 3–13.

    Chapter  Google Scholar 

  13. Goldin, A., Johnson, R. K.: Resistance to antitumor agents. EORTC Monograph Series (In Press) (1977).

    Google Scholar 

  14. Humphreys, S. R., Thomas, L. B., Chirigos, M. A., Goldin, A., Crawford, E. J., Friedkin, M.: Use of dihydrofolate reductase as a biochemical index of chemotherapy. Nature 195, 453–455 (1962).

    Article  PubMed  CAS  Google Scholar 

  15. Humphreys, S. R., Glynn, J. P., Goldin, A.: Suppression of the homograft response by pretreatment with antitumor agents. Transplantation 1, 65 69 (1963).

    Google Scholar 

  16. Jaenke, R. S.: An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab. Invest. 30, 292–304 (1974).

    PubMed  CAS  Google Scholar 

  17. Jaenke, R. S., Colo., St. U: personal communication.

    Google Scholar 

  18. Johnson, R. K., Ovejera, A. A., Goldin, A.: Activity of anthracyclines against an adriamycin (NSC-123127)—resistant subline of P-388 leukemia with special emphasis on cinerubin A (NSC-18334). Cancer Treat. Rep. 60 (1), 99–102 (1976).

    PubMed  CAS  Google Scholar 

  19. Laster, W. R., Jr.: Ridgway osteogenic sarcoma—A promising laboratory model for special therapeutic trials against an advanced—staged, drug-sensitive animal tumor system. Cancer Chemother. Rep. Pt. II, 5 (1), 151–168 (1975).

    Google Scholar 

  20. Lenaz, L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3(3), 111–120(1976).

    Article  PubMed  CAS  Google Scholar 

  21. Myers, C. E., Mcguire, W., Young, R.: Adriamycin: amelioration of toxicity by α-tocopherol. Cancer Treat. Rep. 60 (7), 961 962(1976).

    Google Scholar 

  22. Nicolin, A., Vadlamudi, S., Goldin, A.: Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res. 32, 653–657 (1972).

    PubMed  CAS  Google Scholar 

  23. Ohno, R., Nishikawa, H., Kawashima, K., Uetani, T., Hirano, M., Miura, M., Yamada, K.: Lack of immunosuppressive effect of bleomycin on the primary response of mice to sheep red blood cells. Gann 62, 267(1971).

    CAS  Google Scholar 

  24. Sandberg, J. S., Howsden, F. L., Di Marco, A., Goldin, A.: Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother. Rep. Pt. 1, 54(1), 1–7(1970).

    CAS  Google Scholar 

  25. Schabel, F. M., Jr.: Nitrosoureas: A review of experimental antitumor activity. Cancer Chemother. Rep. 60 (6), 665–698 (1976).

    CAS  Google Scholar 

  26. Schabel, F. M., Jr., Laster, W. R., Jr., Trader, M. W., Witt, M. H.: Combination chemotherapy with cyclophosphamide plus melphalan against leukemia L1210. Proc. Am. Assoc. Cancer Res. 16, 24(1975).

    Google Scholar 

  27. Skipper, H. E., Schabel, F. M., Jr.: Quantitative and Cytokinetic Studies in Experimental Tumor Models. Cancer Medicine. Holland, J. F., Frei, E. (eds.): Phila.: Lea & Febiger 1973, Vol. III, pp. 629–650.

    Google Scholar 

  28. Skipper, H. E., Schabel, F. M., Jr. Trader, M. W., Laster, W. R., Jr.: Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia. Cancer Chemother. Rep. 55, 345–366(1969).

    Google Scholar 

  29. Skipper, H.E., Hutchison, D. J., Schabel, F.M., Jr., Schmidt, L.H., Goldin, A., Brockman, R.W., Venditti, J. M., Wodinsky, I.: A quick reference chart on cross resistance between anticancer agents. Cancer Chemother. Rep. Pt. I, 56 (4), 493–498 (1972).

    CAS  Google Scholar 

  30. Umezawa, H.: Development and mechanism of action of bleomycin. In: New Drug Seminar on Bleomycin. Soper, W. Gott, A.: Natl. Cancer Inst. 1974.

    Google Scholar 

  31. Venditti, J. M.: Relevance of transplantable animal tumor systems to the selectiqn of new agents for clinical trial. In: Pharmacological Basis of Cancer Chemotherapy. Univ. of Texas System Cancer Center, Baltimore: The Williams & Wilkins Co. 1975, pp. 245–270.

    Google Scholar 

  32. Yamaki, H., Tanaka, N., Umezawa, H.: Effects of several tumor-inhibitory antibiotics on immunological response. J. Antibiot. (Tokyo) 22, 315 (1969).

    CAS  Google Scholar 

  33. Young, D. M.: Pathologic effects of adriamycin (NSC-123127) in experimental systems. Cancer Chemother. Rep. Pt. III, 6 (2), 159–175 (1975).

    CAS  Google Scholar 

  34. Zbinden, G., Brandle, E.: Toxicologic screening of daunorubicin (NSC-82151) adriamycin (NSC-123127), and their derivatives in rats. Cancer Chemother. Rep. Pt. I, 59 (4), 707–715 (1975).

    CAS  Google Scholar 

Download references

Authors
  1. A. Goldin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Road, Bldg. B, Suite 200, Palo Alto, California, 94304, USA

    S. K. Carter (Director) (Director)

  2. Department of Antibiotics, National Institutes of Health, Kami-Osaki 2-10-35, Shinagawa-ku, Tokyo, 1411, Japan

    Hamao Umezawa (Head) (Head)

  3. Division of Cancer Treatment, National Cancer Institute, Blair Bldg. Room 4A15, 8300 Colesville Road, Silver Spring, Maryland, 20910, USA

    John Douros

  4. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-Ikebukuro 1-37-1, Toshima-ku, Tokyo, Japan

    Yoshio Sakurai (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Goldin, A. (1978). Criteria for Selection of New Analogs of Antitumor Antibiotics. In: Carter, S.K., Umezawa, H., Douros, J., Sakurai, Y. (eds) Antitumor Antibiotics. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 63. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81219-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81219-4_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81221-7

  • Online ISBN: 978-3-642-81219-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation